Cargando…

Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax

Detalles Bibliográficos
Autores principales:	Rausch, Johanna, Dzama, Margarita M., Dolgikh, Nadezda, Stiller, Hanna L., Bohl, Stephan R., Lahrmann, Catharina, Kunz, Kerstin, Kessler, Linda, Echchannaoui, Hakim, Chen, Chun-Wei, Kindler, Thomas, Döhner, Konstanze, Burrows, Francis, Theobald, Matthias, Sasca, Daniel, Kühn, Michael W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543165/ https://www.ncbi.nlm.nih.gov/pubmed/37102614 http://dx.doi.org/10.3324/haematol.2022.282160

Ejemplares similares

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2022)

PB1761: PRECLINICAL EVALUATION OF THE MENIN INHIBITOR ZIFTOMENIB IN PRIMARY AML SPECIMENS
por: Stevens, Brett, et al.
Publicado: (2023)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
por: Fiskus, Warren, et al.
Publicado: (2022)

A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1
por: Numata, Masashi, et al.
Publicado: (2023)

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
por: Fathi, Amir, et al.
Publicado: (2023)

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
por: Fiskus, Warren, et al.
Publicado: (2023)

Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target
por: Brzezinka, Krzysztof, et al.
Publicado: (2020)

Development of an orally bioavailable selective inhibitor of the menin-MLL
por: Zhong, Hai-Jing, et al.
Publicado: (2022)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Zeidan, Amer M, et al.
Publicado: (2023)

A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin–MLL Inhibition
por: Soto-Feliciano, Yadira M., et al.
Publicado: (2023)

Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin
por: Svoboda, Laurie K., et al.
Publicado: (2016)

The MLL–Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML
por: Rasouli, Milad, et al.
Publicado: (2023)

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
por: Issa, Ghayas C., et al.
Publicado: (2023)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

Multi-omics analyses of MEN1 missense mutations identify disruption of menin–MLL and menin–JunD interactions as critical requirements for molecular pathogenicity
por: Dreijerink, Koen M. A., et al.
Publicado: (2022)

LBODP106 Multi-omics Analyses Of MEN1 Missense Mutations Identify Disruption Of Menin-MLL And Menin-JunD Interactions As Critical Requirements For Molecular Pathogenicity
por: Dreijerink, Koen Marie Anton, et al.
Publicado: (2022)

IKAROS and MENIN Coordinate Therapeutically Actionable Leukaemogenic Gene Expression in MLL-r Acute Myeloid Leukaemia
por: Aubrey, Brandon J., et al.
Publicado: (2022)

Menin–MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers
por: Shi, Qing, et al.
Publicado: (2023)

Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
por: Ye, Jing, et al.
Publicado: (2019)

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
por: Hirsch, Susanne, et al.
Publicado: (2017)

Menin and Menin-Associated Proteins Coregulate Cancer Energy Metabolism
por: Chou, Chih-Wei, et al.
Publicado: (2020)

Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML
por: Ling, Qing, et al.
Publicado: (2023)

High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein–Protein Interaction
por: He, Shihan, et al.
Publicado: (2014)

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
por: Cocciardi, Sibylle, et al.
Publicado: (2019)

Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia
por: Zajac, Malgorzata, et al.
Publicado: (2017)

The role of menin in bone pathology
por: Gorbacheva, Anna, et al.
Publicado: (2022)

FBP1 Is an Interacting Partner of Menin
por: Zaman, Shadia, et al.
Publicado: (2014)

Menin: Expanding and dichotomous roles in cancer
por: Katona, Bryson W., et al.
Publicado: (2019)

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia
por: Tiong, Ing S., et al.
Publicado: (2020)

Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax
por: Fidyt, Klaudyna, et al.
Publicado: (2022)

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
por: Schlenk, Richard F., et al.
Publicado: (2020)

SAT539 Thyroid Cancer Presenting as Aspiration Pneumonia
por: Aslam, Sadia, et al.
Publicado: (2023)

Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review
por: Ma, Julie, et al.
Publicado: (2023)

Investigating the novel-binding site of RPA2 on Menin and predicting the effect of point mutation of Menin through protein–protein interactions
por: Kaur, Gurjeet, et al.
Publicado: (2023)

Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
por: Schlenk, R. F., et al.
Publicado: (2023)

Investigating the Effects of Amino Acid Variations in Human Menin
por: Biancaniello, Carmen, et al.
Publicado: (2022)

Hypothalamic Menin regulates systemic aging and cognitive decline
por: Leng, Lige, et al.
Publicado: (2023)

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis
por: McDuff, Fiona Kate Elizabeth, et al.
Publicado: (2011)

Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model
por: Carter, Bing Z., et al.
Publicado: (2023)

539 Asthma Treatment May Be Useful to Treat Recurrent Wheezing in Infancy
por: Chong Neto, Herberto Jose, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_komp9o7fhrukaqk5mq22kqom95